Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

EXPERIENCE WITH ORTHOCLONE OKT3 MONOCLONAL-ANTIBODY IN LIVER-TRANSPLANTATION AMERICAN JOURNAL OF KIDNEY DISEASES Gordon, R. D., Tzakis, A. G., Iwatsuki, S., Todo, S., Esquivel, C. O., Marsh, J. W., Stieber, A., Makowka, L., Starzl, T. E. 1988; 11 (2): 141-144

Abstract

Experience with the use of Orthoclone OKT3 monoclonal antibody for the treatment of acute cellular rejection in a series of 130 human orthotopic liver transplantations is reviewed. Treatment was highly effective in reversing rejection, in reducing the rate of retransplantation, and in lowering patient mortality. OKT3 was also useful for cyclosporine sparing in patients with poor renal function, hypertension, or CNS toxicity. There was a significant incidence of opportunistic infection associated with the use of OKT3.

View details for Web of Science ID A1988M005600016

View details for PubMedID 3124609

View details for PubMedCentralID PMC2958668